What is the latest VIMTALABS stock price?
The latest stored price for VIMTALABS is Rs 485.55 as of 2026-11-03.
gimli
VIMTALABS stock AI analysis
VIMTALABS Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
VIMTA LABS LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available VIMTALABS price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹485.55
1W return
-4.62%
1M return
-16.91%
3M return
-21.70%
6M return
+6.21%
1Y return
-28.88%
Market cap
₹2,168.92 cr
PE
27.23
PB
4.75
ROE
+19.06%
ROCE
+25.51%
RSI
34.77
Turnover
₹2.77 cr
Why it can matter in screens
- Momentum: VIMTALABS is below 50DMA, below 200DMA; RSI is 34.77.
- Returns: 1D +0.40%, 1W -4.62%, 1M -16.91%, 3M -21.70%, 1Y -28.88%.
- Trend levels: 52W high ₹675.00, 52W low ₹451.55, off high -28.07%.
- Liquidity: latest turnover is ₹2.77 cr; volume vs 20D is +0.49%.
- Valuation/profitability: PE 27.23, PB 4.75, ROE +19.06%, ROCE +25.51%.
- Growth: 3Y sales CAGR +8.93%, 3Y profit CAGR +17.18%.
Quick Answers
Is VIMTALABS above its 50DMA and 200DMA?
VIMTALABS is below 50DMA, below 200DMA. The latest 50DMA is 577.00 and the latest 200DMA is 524.43.
What are VIMTALABS PE, ROE and ROCE?
VIMTALABS has PE 27.23, ROE +19.06%, and ROCE +25.51% in Gimli's latest available snapshot.
How has VIMTALABS performed recently?
VIMTALABS has returned -16.91% over 1 month, -21.70% over 3 months, and -28.88% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 109.07 cr | 41.12 cr | 21.04 cr | 4.71 |
| 2026-03-31 | 109.25 cr | 42.12 cr | 21.11 cr | 4.73 |
| 2025-12-31 | 98.63 cr | 34.45 cr | 17.59 cr | 3.96 |
| 2025-09-30 | 101.85 cr | 36.89 cr | 19.92 cr | 4.46 |
| 2025-06-30 | 97.56 cr | 35.44 cr | 18.89 cr | 4.25 |
| 2025-03-31 | 94.44 cr | 34.68 cr | 18.32 cr | 4.11 |
| 2024-12-31 | 89.92 cr | 34.31 cr | 21.50 cr | 4.83 |
| 2024-09-30 | 84.74 cr | 30.59 cr | 17.02 cr | 3.44 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 407.29 cr | 148.24 cr | 77.51 cr | 17.40 |
| 2025-03-31 | 343.98 cr | 126.12 cr | 67.34 cr | 15.14 |
| 2024-03-31 | 288.60 cr | 98.22 cr | 41.01 cr | 9.26 |
| 2023-03-31 | 315.06 cr | 96.64 cr | 48.17 cr | 10.88 |
| 2022-03-31 | 275.94 cr | 79.84 cr | 41.33 cr | 9.35 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 562.23 cr | 22.97 cr | 3.33 cr | 456.87 cr |
| 2025-03-31 | 466.53 cr | 15.84 cr | 8.52 cr | 378.85 cr |
| 2024-03-31 | 394.47 cr | 13.44 cr | 19.19 cr | 314.12 cr |
| 2023-03-31 | 362.32 cr | 30.50 cr | 14.99 cr | 281.79 cr |
| 2022-03-31 | 307.20 cr | 10.80 cr | 19.34 cr | 233.98 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 147.14 cr | 47.34 cr | n/a |
| 2025-03-31 | 94.05 cr | 14.56 cr | n/a |
| 2024-03-31 | 60.89 cr | -15.68 cr | n/a |
| 2023-03-31 | 87.94 cr | 38.13 cr | n/a |
| 2022-03-31 | 59.07 cr | 20.34 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +35.67% | +4.42% | +0.37% | +0.20% | +59.55% | +0.00% |
| 2026-03-31 | +35.85% | +4.89% | +0.14% | +0.00% | +59.12% | +0.00% |
| 2025-12-31 | +35.90% | +4.59% | +0.11% | +0.00% | +59.41% | +0.00% |
| 2025-09-30 | +35.99% | +4.33% | +0.87% | +0.00% | +58.80% | +0.00% |
| 2025-06-30 | +36.67% | +3.49% | +1.42% | +0.00% | +58.42% | +0.00% |
| 2025-06-14 | +36.67% | +3.52% | +1.42% | +0.00% | +58.39% | +0.00% |
| 2025-03-31 | +36.70% | +3.66% | +1.43% | +0.00% | +58.20% | +0.00% |
| 2024-12-31 | +36.76% | +3.81% | +1.16% | +0.13% | +58.27% | +0.00% |
| 2024-09-30 | +36.89% | +3.31% | +0.00% | +0.00% | +59.80% | +0.00% |
| 2024-06-30 | +36.89% | +5.16% | +1.49% | +1.49% | +56.46% | +0.00% |
| 2024-03-31 | +36.92% | +5.13% | +1.50% | +1.49% | +56.45% | +0.00% |
| 2023-12-31 | +36.98% | +2.88% | +1.49% | +1.49% | +58.66% | +0.00% |
| 2023-09-30 | +37.01% | +2.74% | +1.50% | +1.49% | +58.75% | +0.00% |
| 2023-06-30 | +37.23% | +2.72% | +2.13% | +1.48% | +57.92% | +0.00% |
| 2023-03-31 | +37.24% | +2.25% | +2.14% | +1.48% | +58.38% | +0.00% |
| 2022-12-31 | +37.25% | +2.28% | +2.13% | +1.48% | +58.34% | +0.00% |
| 2022-09-30 | +37.46% | +0.49% | +2.04% | +1.48% | +60.02% | +0.00% |
| 2022-06-30 | +37.46% | +0.00% | +2.36% | n/a | n/a | +0.00% |
| 2022-03-31 | +37.46% | +0.00% | +2.32% | n/a | n/a | +0.00% |
| 2021-12-31 | +37.46% | +0.00% | +2.10% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 424,658.30 cr | 35.053345 | +15.50% | +3.72% |
| DIVISLAB | DIVI S LABORATORIES LTD | 267,167.60 cr | 91.684145 | +18.37% | +47.91% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,377.11 cr | 74.094685 | +16.87% | +28.16% |
| LAURUSLABS | LAURUS LABS LIMITED | 125,408.69 cr | 114.827348 | +21.77% | +138.16% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 124,833.39 cr | 27.818646 | +16.04% | +26.46% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 121,354.29 cr | 57.614911 | +22.62% | +7.87% |
| DRREDDY | DR. REDDY S LABORATORIES | 113,923.95 cr | 40.698752 | +7.80% | +14.41% |
| CIPLA | CIPLA LTD | 112,841.65 cr | 38.950805 | +8.80% | -7.58% |
Try these prompts
- Analyze VIMTA LABS with valuation, momentum and industry peers
- Compare VIMTALABS with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare VIMTALABS with other Healthcare stocks
Data snapshot: 2026-11-03. Not investment advice.